MX388733B - Polvos secos antifungicos. - Google Patents

Polvos secos antifungicos.

Info

Publication number
MX388733B
MX388733B MX2019004322A MX2019004322A MX388733B MX 388733 B MX388733 B MX 388733B MX 2019004322 A MX2019004322 A MX 2019004322A MX 2019004322 A MX2019004322 A MX 2019004322A MX 388733 B MX388733 B MX 388733B
Authority
MX
Mexico
Prior art keywords
dry powders
antifungal
antifungal dry
excipients
stabilizer
Prior art date
Application number
MX2019004322A
Other languages
English (en)
Other versions
MX2019004322A (es
Inventor
Andrew Emmet O'connor
David L Hava
Hillary S Tracy
Jason M Perry
Jean C Sung
Robert Clifford Saunders
Original Assignee
Pulmatrix Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix Operating Co Inc filed Critical Pulmatrix Operating Co Inc
Publication of MX2019004322A publication Critical patent/MX2019004322A/es
Publication of MX388733B publication Critical patent/MX388733B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invención se refiere a formulaciones en polvo seco que comprenden partículas secas respirables que contienen 1) un agente antifúngico en forma de partículas cristalinas, 2) un estabilizante y 3) uno o más excipientes. La invención también se refiere a los polvos secos descritos en este documento para su uso en el tratamiento de la aspergilosis. La invención también se refiere a los polvos secos descritos en este documento para su uso en tratamiento de la aspergilosis broncopulmonar alérgica (ABPA) . La invención también se relaciona con polvos secos descritos en este documento para su uso en el tratamiento de una exacerbación aguda de una enfermedad respiratoria en un individuo.
MX2019004322A 2016-10-14 2017-10-13 Polvos secos antifungicos. MX388733B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662408376P 2016-10-14 2016-10-14
PCT/US2017/056497 WO2018071757A1 (en) 2016-10-14 2017-10-13 Antifungal dry powders

Publications (2)

Publication Number Publication Date
MX2019004322A MX2019004322A (es) 2019-12-11
MX388733B true MX388733B (es) 2025-03-20

Family

ID=60186406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004322A MX388733B (es) 2016-10-14 2017-10-13 Polvos secos antifungicos.

Country Status (12)

Country Link
US (3) US11116722B2 (es)
EP (1) EP3525759A1 (es)
JP (1) JP7085538B2 (es)
KR (1) KR102408798B1 (es)
CN (1) CN109996536B (es)
AU (1) AU2017341815B2 (es)
CA (1) CA3039485A1 (es)
IL (1) IL265913B2 (es)
MX (1) MX388733B (es)
NZ (1) NZ752353A (es)
RU (1) RU2766086C2 (es)
WO (1) WO2018071757A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086367A1 (en) * 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
WO2019204583A1 (en) * 2018-04-18 2019-10-24 Pulmatrix Operating Company, Inc. Antifungal formulations for pulmonary administration comprising itraconazole
CN112423755A (zh) * 2018-04-18 2021-02-26 希普拉技术有限责任公司 治疗真菌感染的方法
WO2021092349A1 (en) * 2019-11-08 2021-05-14 Scynexis, Inc. Lipid-based formulations of scy-078 salts
CN111658610B (zh) * 2020-07-31 2022-05-24 上海方予健康医药科技有限公司 一种供雾化器用的三氮唑类抗真菌药物的混悬液
IT202000030443A1 (it) 2020-12-10 2022-06-10 Zambon Spa Polvere inalabile comprendente voriconazolo in forma cristallina
IT202000030437A1 (it) 2020-12-10 2022-06-10 Zambon Spa Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo
EP4429643A4 (en) * 2021-11-09 2025-11-12 Agency Science Tech & Res Salt-based platform antifungal powder formulation for aerosolization
EP4452235A1 (en) * 2021-12-20 2024-10-30 Pulmatrix Operating Company, Inc. Dry powder formulations of narrow spectrum kinase inhibitors
KR20250053839A (ko) 2022-06-21 2025-04-22 호비온 사이언티아 리미티드 당과 지질 복합입자를 포함하는 흡입용 결정형 약학 조성물 및 제조방법
JP2025527578A (ja) 2022-08-18 2025-08-22 パルマトリックス オペレーティング カンパニー，インコーポレイテッド 吸入用血管新生阻害剤を用いてがんを治療する方法
CA3266383A1 (en) 2022-08-31 2024-03-07 Pulmatrix Operating Company, Inc. METHODS FOR USING DRY ITRACONAZOLE POWDERS
WO2025064631A1 (en) * 2023-09-20 2025-03-27 The Board Of Trustees Of The University Of Illinois Use of a dry powder inhaler to treat or prevent pulmonary fungal infections

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4097620A (en) 1977-05-02 1978-06-27 Xerox Corporation Magnetic toner particle coating process
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
JP2004517127A (ja) 2000-12-21 2004-06-10 ネクター セラピューティックス ポリエン抗真菌剤の肺送達
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
TW200503781A (en) 2002-12-31 2005-02-01 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
KR20120080243A (ko) 2003-05-28 2012-07-16 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
EP1646354A4 (en) 2003-07-22 2010-03-17 Baxter Int SMALL SPHERICAL PARTICLES OF LOW MOLECULAR WEIGHT MOLECULES AND PROCESSES FOR THEIR PREPARATION AND USE
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
EP1789018A1 (en) 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20120128728A1 (en) 2005-12-28 2012-05-24 Novartis Pharma Ag Compositions Comprising Amphotericin B
MX2008015275A (es) * 2006-05-30 2009-02-06 Elan Pharma Int Ltd Formulaciones de posaconazol en nanoparticulas.
CN101500937A (zh) 2006-08-11 2009-08-05 万能药生物有限公司 用于递送活性成分的粒子及其制备方法和组合物
WO2009073843A1 (en) 2007-12-06 2009-06-11 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
NO2252275T3 (es) 2008-02-13 2018-04-28
EP2095816A1 (en) 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CA2840215A1 (en) 2011-06-22 2012-12-27 Abhijit S. BAPAT Conjugate-based antifungal and antibacterial prodrugs
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
IN2012DE00674A (es) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
WO2014106727A1 (en) 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
MX2015013845A (es) * 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
CN104398497B (zh) * 2014-10-29 2017-11-24 中山大学 伊曲康唑吸入粉雾剂及其制备方法
EP3244952A4 (en) * 2015-01-14 2018-11-14 Respira Therapeutics, Inc. Powder dispersion methods and devices
EP3612259B1 (en) 2017-04-17 2022-11-09 Respira Therapeutics, Inc. Unit dose dry powder inhaler

Also Published As

Publication number Publication date
US20250221928A1 (en) 2025-07-10
US20240285523A1 (en) 2024-08-29
CN109996536A (zh) 2019-07-09
NZ752353A (en) 2023-06-30
AU2017341815B2 (en) 2023-06-15
US11116722B2 (en) 2021-09-14
WO2018071757A1 (en) 2018-04-19
IL265913B2 (en) 2024-07-01
RU2766086C2 (ru) 2022-02-07
IL265913B1 (en) 2024-03-01
AU2017341815A1 (en) 2019-05-02
CA3039485A1 (en) 2018-04-19
JP7085538B2 (ja) 2022-06-16
KR102408798B1 (ko) 2022-06-13
RU2019114112A3 (es) 2021-02-12
JP2019534270A (ja) 2019-11-28
KR20190068591A (ko) 2019-06-18
MX2019004322A (es) 2019-12-11
RU2019114112A (ru) 2020-11-16
US20200129428A1 (en) 2020-04-30
EP3525759A1 (en) 2019-08-21
CN109996536B (zh) 2023-03-07
IL265913A (en) 2019-06-30
BR112019007459A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
MX388733B (es) Polvos secos antifungicos.
IL268588A (en) Anti-gprc5d antibodies, compositions comprising same and uses thereof
IL274297A (en) Pyrazolo-piperidine-converted indole-2-carboxamides, preparations containing them and their uses
IL263373A (en) Genetically modified vaccinia virus, preparations containing it and its uses
MX2020006595A (es) Oxadiazoles fungicidas.
IL263355A (en) Nicotine particles and preparations
IL265770A (en) Conjugates are intended for sstr and particles and their formulations
IL282428A (en) History of pyridinyl sulfonamide, pharmaceutical preparations and their uses
EP3415518A4 (en) MACROCYCLUS AND COMPOSITION THEREOF
IL272055A (en) 8,1-naphthyridinone compounds and their uses
SG11202103137WA (en) Stable semaglutide compositions and uses thereof
SG11202105540YA (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
IL268959A (en) Antibodies with cystine mutation, preparations containing them and their uses
FR3029915B1 (fr) Tripeptides, compositions les comprenant et utilisations notamment cosmetiques
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
SG11202002422WA (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
MX2019013250A (es) 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
CL2018002542A1 (es) Na2-imp deshidratada como agente antiaglomerante
MX2020003513A (es) Composiciones de ingredientes activos que comprenden n-alquenoil-n-alquilglucamidas y el uso de los mismos.
HK40112580A (zh) 肽、包含肽的组合物及其应用
Hoshyaripour Volcanic ash particles hold clues to their history and effects
TR201716207A2 (tr) Vilanterol ve umeklidinyum içeren farmasötik formülasyonlar.
MX2018008220A (es) Composiciones cosmeticas que comprenden combinacion sinergica de particulas absorbentes y adsorbentes de sudor y usos de las mismas.